Literature DB >> 9179665

Epidemiologic survey of lower urinary tract symptoms in Asia and Australia using the international prostate symptom score.

Y Homma1, K Kawabe, T Tsukamoto, H Yamanaka, K Okada, E Okajima, O Yoshida, J Kumazawa, F L Gu, C Lee, T C Hsu, R C dela Cruz, A Tantiwang, P H Lim, M A Sheikh, S D Bapat, V R Marshall, K Tajima, Y Aso.   

Abstract

BACKGROUND: The prevalence of lower urinary tract symptoms was determined by survey as an initial step in estimating the significance of benign prostatic hyperplasia (BPH) in Asia and Australia.
METHODS: The symptom index (0 to 35) and quality-of-life (QOL) index (0 to 6) of the international prostate symptom score were measured in 7588 men in 9 Asian countries and 146 men in Australia.
RESULTS: The percentages of Asian men considered to be symptomatic (symptom index > or = 8) were 18%, 29%, 40%, and 56% in the age groups of 40 to 49, 50 to 59, 60 to 69, and 70 to 79 years, respectively. For Australian men, these figures were 36%, 33%, and 37% in the 50 to 59, 60 to 69, and 70 to 79 year age groups, respectively.
CONCLUSIONS: Our estimates indicate that the prevalences of symptomatic men in Asia and Australia are similar to or greater than those in Europe and America, and suggest BPH is similarly common in these areas.

Entities:  

Mesh:

Year:  1997        PMID: 9179665     DOI: 10.1111/j.1442-2042.1997.tb00138.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  29 in total

Review 1.  An overview of prostate diseases and their characteristics specific to Asian men.

Authors:  Shu-Jie Xia; Di Cui; Qi Jiang
Journal:  Asian J Androl       Date:  2012-02-06       Impact factor: 3.285

Review 2.  Efficacy and safety of Chinese herbal medicine for benign prostatic hyperplasia: systematic review of randomized controlled trials.

Authors:  Chun Ho Ma; Wai Ling Lin; Sing Leung Lui; Xun-Yuan Cai; Vivian Taam Wong; Eric Ziea; Zhang-Jin Zhang
Journal:  Asian J Androl       Date:  2013-06-03       Impact factor: 3.285

3.  Frequency and Pattern of Lower Urinary Tract Symptoms in a screened population of Men above 40 Years in Ibadan, Southwestern Nigeria.

Authors:  E O Olapade-Olaopa; E T Owoaje; M M Ladipo; O A Fadimu; O Muoka; T G Adedeji
Journal:  J West Afr Coll Surg       Date:  2015 Oct-Dec

4.  Empirical redefinition of comprehensive health and well-being in the older adults of the United States.

Authors:  Martha K McClintock; William Dale; Edward O Laumann; Linda Waite
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-16       Impact factor: 11.205

5.  Prostatic urethral lift for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.

Authors:  Jae Hung Jung; Balaji Reddy; Karen Ann McCutcheon; Michael Borofsky; Vikram Narayan; Myung Ha Kim; Philipp Dahm
Journal:  Cochrane Database Syst Rev       Date:  2019-05-25

6.  Profile of men's health in Malaysia: problems and challenges.

Authors:  Seng Fah Tong; Wah Yun Low; Chirk Jenn Ng
Journal:  Asian J Androl       Date:  2011-02-28       Impact factor: 3.285

7.  Aquablation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.

Authors:  Eu Chang Hwang; Jae Hung Jung; Michael Borofsky; Myung Ha Kim; Philipp Dahm
Journal:  Cochrane Database Syst Rev       Date:  2019-02-13

8.  Assessment of voiding dysfunction in Parkinson's disease by the international prostate symptom score.

Authors:  I Araki; S Kuno
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-04       Impact factor: 10.154

9.  Comparative Analysis of Outcomes after Transurethral Resection of the Prostate according to Prostate Shape Shown by Transrectal Ultrasonography.

Authors:  Hyo Serk Lee; Sung Jin Kim; Jae Mann Song; Kwang Jin Kim; Hyun Chul Chung
Journal:  Korean J Urol       Date:  2010-07-20

10.  Men's lower urinary tract symptoms are also mental and physical sufferings for their spouses.

Authors:  Sae Chul Kim; Shin Young Lee
Journal:  J Korean Med Sci       Date:  2009-04-20       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.